Placebo/Saline

DRUG4 trials

Sponsors

Icahn School of Medicine at Mount Sinai, VA Office of Research and Development, MenoGeniX, Inc., Swedish Institute for Infectious Disease Control

Conditions

Autism Spectrum DisorderHIV/AIDSPTSDPostmenopausal SymptomsPosttraumatic Stress Disorder

Phase 1

A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women

CompletedNCT03640754

MenoGeniX, Inc.Postmenopausal Symptoms

Start: 2018-08-06End: 2022-02-22Updated: 2023-11-28

Phase 2

A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

TerminatedNCT01970345

Icahn School of Medicine at Mount SinaiAutism Spectrum Disorder

Start: 2014-05-31End: 2017-09-13Updated: 2024-02-08

CAP-Ketamine for Antidepressant Resistant PTSD

CompletedNCT02655692

VA Office of Research and DevelopmentPosttraumatic Stress Disorder, PTSD

Start: 2016-04-18End: 2020-07-01Updated: 2022-06-02

Unknown Phase

RecruitingPACTR201211000435126

Swedish Institute for Infectious Disease ControlHIV/AIDS

Start: 2012-12-03Target: 198Updated: 2026-09-14

Related Papers

Association of Thyroid Hormone and Insulin-Like Growth Factor-1 Levels With Autism Spectrum Disorders: A Systematic Review and Meta-Analysis.

2025-05-12

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial.

2022-01-1969 citations